戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 wn tumor suppressor gene (TSG) for malignant rhabdoid and childhood central nervous system tumors.
2 ted in decreased colony-forming potential in rhabdoid and NSCLC tumor cells, thereby demonstrating fu
3                                              Rhabdoid brain tumours, also called atypical teratoid rh
4 f the complex has been found mutated in both rhabdoid cell lines and in primary rhabdoid tumors.
5  lines, the BAF47 protein was missing in all rhabdoid cell lines and one RMS cell line.
6 ed with those observed with SMARCB1-negative rhabdoid cell lines in which SMARCB1 re-expression cause
7                                        Using rhabdoid cell lines overexpressing WT1, we show that WT1
8 yclin D1, induced G1 arrest and apoptosis in rhabdoid cell lines.
9 chorage-dependent and -independent growth of rhabdoid cells and caused synergistic induction of cell
10 at INI1 represses Cyclin D1 transcription in rhabdoid cells by directly recruiting histone deacetylas
11  found that RNA interference of cyclin D1 in rhabdoid cells was sufficient to induce G1 arrest and ap
12 e tumors developed in these Ini1+/- mice are rhabdoid, defective for Ini1 protein, and like the human
13  and PBRM1 in a few RCCs was associated with rhabdoid features (q = 0.0007).
14 h poorly differentiated tumors with variable rhabdoid features.
15 euroectodermal tumors, and atypical teratoid/rhabdoid-like tumors from postnatal mouse neural stem/pr
16 ucleus, the rostromedial tegmental area, the rhabdoid nucleus, the mesencephalic raphe nuclei, and th
17 NA sequencing of the adverse sarcomatoid and rhabdoid phenotypes uncover gene signatures and potentia
18       Overexpression of HOTS inhibits Wilms, rhabdoid, rhabdomyosarcoma, and choriocarcinoma tumor ce
19                              Sarcomatoid and rhabdoid (S/R) renal cell carcinoma (RCC) are highly agg
20 raniopharyngioma (16), and atypical teratoid rhabdoid tumor (12).
21                            Atypical Teratoid Rhabdoid Tumor (AT/RT) is a rare pediatric central nervo
22                            Atypical teratoid/rhabdoid tumor (AT/RT) is an aggressive, early-childhood
23                            Atypical teratoid/rhabdoid tumor (AT/RT) of the CNS is an extremely rare a
24 mors (sPNET) correspond to atypical teratoid/rhabdoid tumor (AT/RT), a rare childhood tumor.
25 t rhabdoid tumors, such as atypical teratoid/rhabdoid tumor (AT/RT).
26                            Atypical teratoid rhabdoid tumor (ATRT) is an aggressive embryonal brain t
27                            Atypical teratoid/rhabdoid tumor (ATRT) is one of the most common brain tu
28                            Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant n
29                                    Malignant rhabdoid tumor (MRT) is an aggressive, highly lethal can
30 F5 function is usually observed in malignant rhabdoid tumor (MRT), a highly aggressive pediatric neop
31     We find that Ewing sarcoma and malignant rhabdoid tumor (MRT), two pediatric cancers that are sen
32 astoma multiforme (n = 2), atypical teratoid/rhabdoid tumor (n = 1), malignant glioma (n = 1), and ch
33 n = 5), germinoma (n = 3), atypical teratoid rhabdoid tumor (n = 2), choroid plexus carcinoma (n = 2)
34 F mutations drive cancer, we contributed ten rhabdoid tumor (RT) cell lines mutant for SWI/SNF subuni
35  selected rare tumors (ie, atypical teratoid/rhabdoid tumor and CNS primitive neuroectodermal tumor).
36 ency (D(max)) > 90% against BRD9 in the G401 rhabdoid tumor and HS-SY-II synovial sarcoma cell lines
37 blastoma, glioblastoma and atypical teratoid rhabdoid tumor cell lines.
38 he tumor suppressor gene CDKN2A in malignant rhabdoid tumor cells reactivates the gene and induces se
39 e performed CRISPR screens in SMARCB1-mutant rhabdoid tumor cells to identify genetic contributors to
40 first revealed by cell viability assays that rhabdoid tumor cells' sensitivity to homoharringtonine w
41 ed SMARCB1 potential roles in translation in rhabdoid tumor cells.
42  mediate PGBD5-induced DNA rearrangements in rhabdoid tumor cells.
43  study is to determine prognostic factors in rhabdoid tumor of the kidney (RTK), including both demog
44            The G401 cell line derived from a rhabdoid tumor of the kidney secretes the heparin-bindin
45  predispose to two distinct tumor syndromes: rhabdoid tumor predisposition syndrome, with malignant p
46 abdoid tumors for mutations in the candidate rhabdoid tumor suppressor gene, INI1.
47 on in 22q11, was identified as the candidate rhabdoid tumor suppressor gene.
48 e retained super-enhancers are essential for rhabdoid tumor survival, including some that are shared
49 inoma, medulloblastoma and atypical teratoid rhabdoid tumor) respond to JQ1 even when harboring genet
50  driving roles first identified in malignant rhabdoid tumor, an aggressive pediatric cancer character
51 ation for the treatment of synovial sarcoma, rhabdoid tumor, and other BRD9-dependent human diseases.
52 umor suppressor gene hSNF5/INI1 in malignant rhabdoid tumor, and the association of c-kit mutations w
53 e Beckwith-Wiedemann syndrome patients and a rhabdoid tumor.
54 e derepression of this gene is essential for rhabdoid tumorigenesis.
55 ma (AAIR 0.14 cases/1 million) and malignant rhabdoid tumors (0.06 cases/1 million) were most common.
56 ve pediatric atypical teratoid and malignant rhabdoid tumors (AT/RT).
57  these tumors are known as atypical teratoid/rhabdoid tumors (AT/RT).
58 mutations can give rise to atypical teratoid/rhabdoid tumors (AT/RTs) in the pediatric central nervou
59                            Atypical teratoid rhabdoid tumors (ATRT) are incurable high-grade pediatri
60 mark genetic aberration of atypical teratoid rhabdoid tumors (ATRT).
61 lecular intertumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs)
62 ecular inter-tumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs)
63                            Atypical teratoid rhabdoid tumors (ATRTs) are challenging pediatric brain
64  We recently reported that atypical teratoid rhabdoid tumors (ATRTs) comprise at least two transcript
65                            Atypical teratoid/rhabdoid tumors (ATRTs) typically arise in the central n
66 enic dependency on EZH2 in atypical teratoid rhabdoid tumors (ATRTs), but the underlying mechanism ha
67                                    Malignant rhabdoid tumors (MRT) are highly aggressive pediatric ca
68                                    Malignant rhabdoid tumors (MRT) are rare aggressive cancers that o
69                                    Malignant rhabdoid tumors (MRT) are rare but deadly pediatric tumo
70  and a tumor suppressor mutated in malignant rhabdoid tumors (MRT).
71 emodeling complex, is lost in most malignant rhabdoid tumors (MRT).
72                                    Malignant rhabdoid tumors (MRTs) are rare lethal tumors of childho
73 mutations that result primarily in malignant rhabdoid tumors (MRTs) in humans and MRTs as well as oth
74 s extremely prevalent in pediatric malignant rhabdoid tumors (MRTs) or atypical teratoid rhabdoid tum
75 d embryonic mosaic mouse models of malignant rhabdoid tumors (MRTs) that faithfully recapitulate the
76 F5), which is inactivated in human malignant rhabdoid tumors (MRTs), interacts with GLI1.
77 se clinical outcomes for pediatric malignant rhabdoid tumors (MRTs).
78 ts of medulloblastomas (n = 2325), malignant rhabdoid tumors (n = 229) and pediatric high-grade gliom
79 y and minimum tumor ADC in atypical teratoid rhabdoid tumors (rho = -0.786, P < .05).
80                                              Rhabdoid tumors (RT) are aggressive pediatric malignanci
81                                              Rhabdoid tumors (RTs) are aggressive and currently incur
82                                              Rhabdoid tumors (RTs) are rare, highly aggressive pediat
83 pecific vulnerability in pediatric malignant rhabdoid tumors (RTs), which are driven by inactivation
84              SMARCB1 mutations predispose to rhabdoid tumors and schwannomas but the mechanisms under
85 an SWI/SNF complexes occur in most malignant rhabdoid tumors and some other malignancies.
86 n about the biology and clinical behavior of rhabdoid tumors and to begin to develop treatment strate
87                                              Rhabdoid tumors are aggressive pediatric malignancies fo
88                                              Rhabdoid tumors arise because of the loss of the tumor s
89                                    Malignant rhabdoid tumors arise in several anatomic locations and
90 sociated with the poor prognosis seen in all rhabdoid tumors but only some RMS.
91 distinguishable mutational landscapes, human rhabdoid tumors exhibit distinct enhancer H3K27ac signat
92  genetically engineered models for malignant rhabdoid tumors exist, none of them recapitulate AT/RT,
93 rs of the brain and 7 renal and 4 extrarenal rhabdoid tumors for mutations in the candidate rhabdoid
94 is study reveals that the loss of SMARCB1 in rhabdoid tumors has specific consequences on mRNAs trans
95  the requirement of Cyclin D1 for genesis of rhabdoid tumors in vivo, we developed Ini1 heterozygous
96 gh a mechanism that is distinct from that of rhabdoid tumors in which SMARCB1 protein is completely a
97 y INI1 and Cyclin D1 overexpression in human rhabdoid tumors is a common phenomenon.
98 ogeneity observed in patients with malignant rhabdoid tumors is unknown.
99 clear chromatin-remodeling factor SMARCB1 in rhabdoid tumors led to increased phosphorylation of eIF2
100  lineage, while group 2a/b atypical teratoid/rhabdoid tumors may originate outside the neuroectoderm.
101         We examined 18 atypical teratoid and rhabdoid tumors of the brain and 7 renal and 4 extrarena
102 ygously or homozygously deleted in pediatric rhabdoid tumors of the brain, kidney and soft tissues.
103  INI1 is a tumor suppressor gene involved in rhabdoid tumors of the brain, kidney, and other extraren
104    A workshop on childhood atypical teratoid/rhabdoid tumors of the central nervous system, sponsored
105 enografts of WiT49 cells resembled malignant rhabdoid tumors rather than Wilms tumors.
106 ich SMARCB1 germline mutations predispose to rhabdoid tumors versus schwannomas are still unknown.
107 dels and show that early Smarcb1 loss causes rhabdoid tumors whereas loss at later stages combined wi
108  or stem cell transplant in the treatment of rhabdoid tumors will be published separately.
109                          A series of primary rhabdoid tumors with chromosome 22q11 deletions were scr
110 (e.g., lung, synovial sarcoma, leukemia, and rhabdoid tumors).
111 itive neuroectodermal tumor, ependymoma, and rhabdoid tumors, 5-year EFS rates were 32% +/- 5%, 17% +
112 g mutations of the SMARCB1 gene in malignant rhabdoid tumors, a highly aggressive childhood cancer.
113 epatoblastomas, 7 of 8 Wilms' tumors, 3 of 3 rhabdoid tumors, and 12 of 27 adenocarcinomas also teste
114  complexes in synovial sarcoma and malignant rhabdoid tumors, both of which possess aberrations in ca
115                                              Rhabdoid tumors, characterized and driven by the loss of
116           Here we sequenced the exomes of 35 rhabdoid tumors, highly aggressive cancers of early chil
117  identified in children with brain and renal rhabdoid tumors, indicating that INI1 is a tumor suppres
118 tumor (WT) share a similar genetic link with rhabdoid tumors, it was hypothesized that they may also
119                         In atypical teratoid rhabdoid tumors, no correlation was found between cellul
120 ially involved in the formation of malignant rhabdoid tumors, such as atypical teratoid/rhabdoid tumo
121 osely resemble those of human Snf5-deficient rhabdoid tumors.
122 ed sarcoma (US), osteosarcoma, and malignant rhabdoid tumors.
123 toid tumor of the brain and three with renal rhabdoid tumors.
124 d in both rhabdoid cell lines and in primary rhabdoid tumors.
125 ir absence contributes to the progression of rhabdoid tumors.
126 image-guided metabolic radiosensitization of rhabdoid tumors.
127 luding medulloblastoma and atypical teratoid/rhabdoid tumors.
128  of childhood solid tumors, including lethal rhabdoid tumors.
129 per-enhancers, such as SOX2 in brain-derived rhabdoid tumors.
130 cal features and molecular profiles of human rhabdoid tumors.
131 ly undefined genomic rearrangements in human rhabdoid tumors.
132 plex, is inactivated in nearly all pediatric rhabdoid tumors.
133  1 hepatocellular carcinoma, and 2 malignant rhabdoid tumors.
134 uppressor in familial and sporadic malignant rhabdoid tumors.
135  WHO grade III), and seven atypical teratoid rhabdoid tumors.
136  rhabdoid tumors (MRTs) or atypical teratoid rhabdoid tumors.
137 nt a therapeutic target in atypical teratoid/rhabdoid tumors.
138 ly effective as novel therapeutic agents for rhabdoid tumors.
139 yclin D1 is a key mediator in the genesis of rhabdoid tumors.
140 iatric medulloblastoma and atypical teratoid rhabdoid tumour (ATRT) cells to ZIKV infection.
141                                    Malignant rhabdoid tumour (MRT) is an often lethal childhood cance
142 lices derived from a human atypical teratoid-rhabdoid tumour at three spatial resolutions, the highes
143 , congenital mesoblastic nephroma, malignant rhabdoid tumour of the kidney, renal-cell carcinoma, ren
144 al analyses identified two atypical teratoid rhabdoid tumour subgroups with differential enrichment o
145 a, lymphoepithelial carcinoma, and malignant rhabdoid tumour); the proportion of patients with an obj
146  sarcoma, (congenital) mesoblastic nephroma, rhabdoid tumour, and renal medullary carcinoma form a he
147  sarcoma, (congenital) mesoblastic nephroma, rhabdoid tumour, and renal medullary carcinoma.
148 -synonymous FBXW7 mutation in a child with a rhabdoid tumour.
149 ed chromosomal translocation in an embryonal rhabdoid tumour.
150 ctodermal tumours (PNETs), atypical teratoid/rhabdoid tumours (AT/RTs) and malignant gliomas.
151                                 Extracranial rhabdoid tumours are rare, and often occur in infants.
152 m epithelial cells, differentiating RMC from rhabdoid tumours arising from neural crest cells.
153                              We obtained 259 rhabdoid tumours from 37 international institutions and
154       Despite multimodal therapy, outcome in rhabdoid tumours remains poor with only 31% of patients
155  a cohort of patients with atypical teratoid rhabdoid tumours to find out the molecular basis for cli
156 brain tumours, also called atypical teratoid rhabdoid tumours, are lethal childhood cancers with char
157 y cancer, including Wilms tumours, malignant rhabdoid tumours, renal cell carcinomas, and congenital
158 ification of patients with atypical teratoid rhabdoid tumours.
159 ver molecular subgroups of atypical teratoid rhabdoid tumours.

 
Page Top